Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 7, Issue 6, Pages 731-745Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2014.950655
Keywords
cognition; major depressive disorder; multimodal antidepressant; review; vortioxetine
Categories
Funding
- Lundbeck
Ask authors/readers for more resources
Vortioxetine (Brintellix (R), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine administration induces antidepressant- and anxiolytic-like effects, and can enhance cognitive performance in rodents. Several clinical trials have reported the efficiency and a satisfactory tolerability of vortioxetine treatment in depressed patients. Remarkably, vortioxetine has a specific positive impact on cognitive symptoms in depressed patients. Overall, vortioxetine is an efficacious antidepressant drug for the treatment of patients with a major depressive episode and has a unique mechanism of action offering a new therapeutic option.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available